AEON
AEON Biopharma, Inc.
NYSE MKT: AEON · HEALTHCARE · BIOTECHNOLOGY
$0.95
-3.02% today
Updated 2026-04-29
Market cap
$24.16M
P/E ratio
—
P/S ratio
97.16x
EPS (TTM)
$-3.95
Dividend yield
—
52W range
$0 – $1
Volume
0.1M
AEON Biopharma, Inc. (AEON) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-87.4%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
-207.2%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-2.3%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-7.4%
2025-11-14
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2025-12-31 | $-3.72 | -1714.6% | $1.08 | $1.11 | +2.8% |
| 2025-11-14 | $-0.39 | +9.3% | $0.94 | $0.87 | -7.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.21 | $-3.72 | -1714.6% | — | — |
| 2025-09-30 | $-0.43 | $-0.39 | +9.3% | — | — |
| 2025-06-30 | $-0.35 | $-0.60 | -71.4% | — | — |
| 2025-03-31 | — | $2.28 | — | — | — |
| 2024-12-31 | — | $3.47 | — | — | — |
| 2024-09-30 | $-11.52 | $-11.52 | +0.0% | — | — |
| 2024-06-30 | $-13.68 | $5.34 | +139.0% | — | — |
| 2024-03-31 | $-0.31 | $-0.28 | +9.7% | — | — |
| 2023-12-31 | $-0.40 | $-0.71 | -77.5% | — | — |
| 2023-09-30 | $-0.53 | $1.15 | +317.0% | — | — |
| 2023-06-30 | — | $-31.88 | — | — | — |
| 2023-03-31 | — | $-1.40 | — | — | — |
Frequently asked questions
Has AEON Biopharma, Inc. beaten earnings estimates?
AEON Biopharma, Inc. has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -87.4% over the last 3 quarters.
How does AEON stock react to earnings?
AEON stock has moved an average of -2.3% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.